Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2017 (2017), Article ID 4803262, 5 pages
Research Article

Clostridium difficile in Inflammatory Bowel Disease: A Retrospective Study

1Department of Medicine, University of Massachusetts School of Medicine, 55 Lake Avenue North, Worcester, MA 01604, USA
2Department of Gastroenterology, University of California Los Angeles, Los Angeles, CA, USA
3Department of Gastroenterology, Aurora Healthcare, Milwaukee, WI, USA
4Department of Medicine, University of Massachusetts, Worcester, MA, USA
5Department of Gastroenterology, University of Massachusetts, Worcester, MA, USA

Correspondence should be addressed to William Gillespie

Received 6 June 2017; Accepted 24 July 2017; Published 4 October 2017

Academic Editor: Paolo Gionchetti

Copyright © 2017 William Gillespie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Aim. To investigate the epidemiology and risk factors of Clostridium difficile infections (CDI) in patients with inflammatory bowel disease (IBD). Methods. This is a retrospective study of patients diagnosed with IBD. 1006 charts were screened and 654 patients met the inclusion criteria. Patients were divided into 2 cohorts based on the presence of prior diagnosis of CDI. Statistical analysis with Pearson’s chi-squared and two-sample t-test was performed. Results. The incidence of CDI among IBD patients was 6.7%. There was equal prevalence of CDI among Crohn’s disease (CD) (, 49%) and ulcerative colitis (UC) (, 51%). IBD patients acquired CDI at a mean age of 42.7 years, with 56% of infections acquired in the community and only 28% associated with healthcare. Only 30% of IBD patients with CDI had prior antibiotic use, and 16% had prior steroid use. IBD patients were significantly more likely to require biologic therapy (57% versus 37%, ) and have extraintestinal manifestations of IBD (43% versus 28%, ). Conclusions. IBD patients are more susceptible to CDI at a younger age and often lack traditional risk factors. IBD patients with at least one CDI were more likely to require biologic therapy and had greater rates of extraintestinal manifestations.